Wedbush Issues Positive Estimate for argenx Earnings

argenx SE (NASDAQ:ARGX) – Investment analysts at Wedbush increased their Q1 2025 earnings per share (EPS) estimates for argenx in a report issued on Thursday, October 31st. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $1.91 for the quarter, up from their prior forecast of $1.83. Wedbush has a “Outperform” rating and a $560.00 price target on the stock. The consensus estimate for argenx’s current full-year earnings is ($0.22) per share. Wedbush also issued estimates for argenx’s Q2 2025 earnings at $2.23 EPS and Q3 2025 earnings at $2.62 EPS.

Several other analysts have also weighed in on ARGX. Wells Fargo & Company lifted their target price on shares of argenx from $547.00 to $639.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Barclays upgraded argenx from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, August 6th. Deutsche Bank Aktiengesellschaft downgraded argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Truist Financial upped their price target on argenx from $540.00 to $660.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $615.50.

argenx Price Performance

ARGX opened at $602.47 on Monday. The company has a market capitalization of $36.03 billion, a P/E ratio of -676.82 and a beta of 0.61. The firm’s fifty day moving average price is $540.89 and its two-hundred day moving average price is $468.81. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $611.22.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $1.29. The company had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter last year, the firm earned ($1.25) EPS.

Institutional Trading of argenx

Several hedge funds have recently modified their holdings of ARGX. FORA Capital LLC bought a new position in argenx in the 1st quarter valued at $2,024,000. Central Pacific Bank Trust Division acquired a new stake in argenx in the first quarter worth about $313,000. Mediolanum International Funds Ltd bought a new stake in argenx during the 1st quarter worth about $4,570,000. Envestnet Portfolio Solutions Inc. lifted its position in argenx by 21.5% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 1,300 shares of the company’s stock valued at $512,000 after purchasing an additional 230 shares during the period. Finally, Oppenheimer Asset Management Inc. boosted its stake in shares of argenx by 5.5% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 2,916 shares of the company’s stock valued at $1,148,000 after purchasing an additional 152 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.